wellness

The state of being in great health, and continually striving to attain all of your goals.

Pulmonary Embolism: Symptoms, Causes, Treatment, and Prevention of a Silent Killer
Introduction Pulmonary embolism (PE) is a serious, potentially life-threatening condition that occurs when a blood clot blocks one or more arteries in the lungs. It is one of the most critical emergencies in cardiovascular health, ranking just after heart attacks and strokes in terms of morbidity and mortality. PE often originates from deep vein thrombosis (DVT), a blood clot in the veins of the legs or pelvis, that travels through the bloodstream to the lungs. Understanding the risk factors, early symptoms, diagnostic methods, treatment options, and preventive strategies is essential to improving outcomes and saving lives.
By Story Prism21 days ago in Longevity
The First Step Toward True Health
Have you noticed how horribly sick everyone is these days? Over 75% of people have one chronic health disease... 50% have two or more...
By Dr. Cody Dakota Wooten, DFM, DHM, DAS (hc)22 days ago in Longevity
The Healthiest People I Know Do Less Than You Think. Here's Their Actual Routine.
Two-hour gym sessions. Strict meal plans. Supplements lined up on the counter. A level of discipline that bordered on obsession.
By Destiny S. Harris22 days ago in Longevity
Novo Nordisk Sues Hims & Hers Over Cheaper Copycat Wegovy Pills and Injections. AI-Generated.
In a significant legal development in the pharmaceutical industry, Novo Nordisk, the maker of the popular weight loss drug Wegovy, has filed a lawsuit against Hims & Hers Health Inc., accusing the company of producing and selling cheaper, copycat versions of Wegovy’s pills and injections. The lawsuit, which has raised concerns about intellectual property rights, competition, and the future of weight loss treatments, has sent shockwaves through the healthcare market.
By Ayesha Lashari22 days ago in Longevity
Why More and More Seniors Are Spending Time at McDonald’s
It only takes a few minutes sitting inside a McDonald’s, at almost any time of day, to notice a quiet but meaningful phenomenon. Elderly people are there. Sometimes alone, sometimes in pairs, sometimes simply seated with a coffee or a barely touched tray. They take their time. They observe. They watch life move around them. Nothing dramatic. Nothing noisy. And yet, their presence speaks volumes.
By Bubble Chill Media 22 days ago in Longevity
Discovering the Unexpected Serenity of Walking Meditations
“I found that one of the hardest things about mindfulness practice was to let go of effort. For years, I treated meditation as one more item on my daily to-do list — mindfulness…check. This task orientation turned meditation into a chore that I could do incorrectly.” — Seth J. Gillihan, PhD, Mindful Cognitive Behavioral Therapy: A Simple Path to Healing, Hope, and Peace
By Leigh Victoria Phan, MS, MFA22 days ago in Longevity
Novo Nordisk Sues Hims & Hers Over Cheaper Copycat Wegovy Pills and Injections. AI-Generated.
If you’ve been following the weight-loss drug boom, you’ve probably heard of Wegovy, the blockbuster injection from Novo Nordisk. But recently, the story took a dramatic twist: Novo Nordisk is suing Hims & Hers, the popular telehealth company, over cheaper, copycat versions of the drug. Here’s everything you need to know about this high-stakes legal clash and what it means for patients, telehealth companies, and the pharmaceutical industry. What Happened? Novo Nordisk, the Danish pharmaceutical giant behind Wegovy, has filed a patent infringement lawsuit against Hims & Hers in a Delaware federal court. The lawsuit claims that Hims & Hers marketed unapproved, compounded versions of semaglutide — Wegovy’s active ingredient — as cheaper alternatives to the brand-name drug. According to Novo Nordisk, Hims & Hers’ actions not only infringe on its patents but also bypass important safety regulations. The pharmaceutical company is asking the court to issue a permanent injunction to stop Hims & Hers from selling these products and is seeking damages for lost profits. Why Wegovy Matters Wegovy isn’t just another weight-loss medication — it’s one of Novo Nordisk’s most profitable and fastest-growing products. It works by using GLP-1 technology, which helps regulate appetite and glucose levels. The drug’s success has made it a key part of the global weight-loss and diabetes market, with competitors like Eli Lilly racing to develop similar treatments. With prices for Wegovy often reaching several hundred dollars per month, the market for cheaper alternatives is huge. That’s where Hims & Hers saw an opportunity — but it may have crossed a legal line. What Hims & Hers Did Hims & Hers, best known for online prescriptions and telehealth services, briefly offered a compounded semaglutide pill for as low as $49 for the first month. Compounded drugs are made by pharmacies by mixing ingredients to meet specific patient needs. While compounding is legal in some cases, it doesn’t require FDA approval in the same way as branded drugs. That means quality, dosage, and safety can vary significantly. Novo Nordisk argues that Hims & Hers went beyond legal compounding rules by mass-marketing unapproved semaglutide products that directly compete with Wegovy. Within days of launching the pill, Hims & Hers pulled it from the market, citing regulatory pressure and discussions with the FDA. Despite this, Novo Nordisk says other forms, including injectable versions of the compounded drug, are still being offered, prompting the lawsuit. Legal and Regulatory Stakes The case highlights the tension between drug safety, patent protection, and affordability. Novo Nordisk holds semaglutide patents until the early 2030s, covering both oral and injectable versions. The company argues that protecting these patents ensures patients receive medications that are safe, tested, and effective. For Hims & Hers, the case raises questions about patient access to lower-cost medications. Telehealth companies have grown rapidly during the pandemic by offering convenient, direct-to-consumer treatments. Some argue that compounded drugs can make high-cost medications more accessible — but the trade-off can be safety and regulatory compliance. The FDA has warned that unapproved weight-loss drug copies could pose risks to patients, citing potential inconsistencies in dosing and quality. This regulatory scrutiny adds another layer to the legal battle. Market and Investor Impact The news of the lawsuit has already affected the stock market. Hims & Hers’ shares dropped, while Novo Nordisk’s stock rose, signaling investor confidence in the company’s move to defend its drug patents. Analysts are closely watching this case as an indicator of how the growing GLP-1 weight-loss market will handle competition and pricing pressure. Some experts believe this lawsuit is part of a broader trend where big pharma pushes back against low-cost competitors. Others argue it highlights the ongoing debate over access to affordable treatments versus innovation and safety. What This Means for Patients For patients, this legal battle is a reminder of the risks and rewards of new weight-loss treatments. On one hand, cheaper alternatives can make medications like semaglutide more accessible. On the other, unapproved compounded drugs may not meet the same safety standards as FDA-approved options. Anyone considering weight-loss drugs should consult a licensed healthcare provider and carefully weigh the pros and cons of brand-name versus compounded medications. The Road Ahead The lawsuit will likely play out over months, possibly even years. Novo Nordisk is committed to defending its patents and challenging unapproved competition, while Hims & Hers may argue for affordability and patient access. Regulatory agencies, particularly the FDA, will continue to play a crucial role in determining what’s allowed in the fast-growing telehealth and weight-loss market. For now, patients and investors alike are keeping a close eye on this legal showdown — a case that could shape the future of obesity drugs in the U.S. Key Takeaways Novo Nordisk sues Hims & Hers for selling unapproved semaglutide alternatives. The dispute centers on patent infringement and drug safety concerns. Compounded drugs are cheaper but not FDA-approved and can vary in quality. The outcome could affect the booming GLP-1 weight-loss market and telehealth business models. This case is more than a legal fight; it’s a clash between innovation, accessibility, and regulation — and the stakes couldn’t be higher for patients, companies, and investors in the rapidly expanding weight-loss drug industry.
By Abid Ali22 days ago in Longevity
Wellness for Therapists: Small Adjustments That Make a Big Difference
The good news? Improving your well-being doesn’t require a dramatic life overhaul. Sometimes, small tweaks in your routine, environment, or mindset can lead to big shifts in how you feel and function. Below are some practical, easy-to-implement ideas designed specifically for therapists who want to feel better, work smarter, and bring more joy into their daily grind.
By Vala Flynn23 days ago in Longevity
From Greggs Loyalists to Jab Addicts: How Weight-Loss Drugs Are Emptying Bakery Queues. AI-Generated.
The Morning Queue That Started to Vanish For decades, the early‑morning queue outside a Greggs bakery served as a reliable barometer of British life. Commuters clutched paper cups of tea, builders debated football scores, and the scent of warm sausage rolls drifted down the high street. However, in recent years, something subtle yet striking has changed. The queues, once snaking around the corner, now thin out faster than expected. Consequently, observers began asking a question that felt almost heretical: where did everyone go?
By Alex23 days ago in Longevity
Why People Crave Physical Touch
Have you ever wondered why a simple hug can feel so comforting? Or why holding someone’s hand can instantly make you feel safe?
By Artical Media23 days ago in Longevity
Common Intimacy Mistakes Couples Make
Intimacy is one of the most important parts of a strong and lasting relationship. But for many couples, intimacy slowly fades over time—not because love disappears, but because small mistakes build up without anyone noticing.
By Artical Media23 days ago in Longevity
Roots and Fruit
Most people evaluate life by what shows. Results, behavior, success, failure, growth, collapse. Fruit is easier to measure than roots, so it becomes the focus almost by default. When something goes wrong, attention rushes to what is visible and immediate. When something goes right, credit is assigned to the most recent action. But this way of seeing consistently misreads causality. Fruit is never the beginning of the story. It is the result of something that has been growing quietly, often unnoticed, for a long time.
By Peter Thwing - Host of the FST Podcast23 days ago in Longevity